ESR1 Mutated Metastatic Breast Cancer Diagnostics Market
Market Survey on ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment
An In-depth Market Insights of ESR1 Mutated Metastatic Breast Cancer Diagnostics Market including Tamoxifen, Aromatase inhibitors, Ovarian suppression, Fulvestrant, and Elacestrant Covering 30+ Countries like United States, United Kingdom, Germany, France, Norway, Sweden, Saudi Arabia, United Arab Emirates, Japan, Korea, Australia, New Zealand, and Others
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Snapshot
The global ESR1 mutated metastatic breast cancer diagnostics market garnered a market value of US$ 58.70 Million in 2022 and is expected to accumulate a market value of US$ 185 Million by registering a CAGR of 11% in the forecast period 2023 to 2033. Growth of the ESR1 mutated metastatic breast cancer diagnostics market can be attributed to increasing prevalence of breast cancer and the growing need for personalized treatment options for patients with specific genetic mutations. The market for ESR1 mutated metastatic breast cancer diagnostics market registered a CAGR of 6.9% in the historical period 2018 to 2022.
ESR1 is a gene that encodes for the estrogen receptor alpha protein, which plays a crucial role in regulating the growth and development of breast tissue. Mutations in this gene are found in approximately 30-40% of metastatic breast cancer patients and can lead to resistance to hormone therapy, a common treatment for breast cancer.
Diagnostics in this market may include genetic testing to detect ESR1 mutations, imaging tests to monitor disease progression, and other biomarker tests to aid in the diagnosis and treatment of ESR1 mutated metastatic breast cancer.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 65.15 Million |
|
Anticipated Forecast Value (2033) |
US$ 185 Million |
|
Projected Growth Rate (2023 to 2033) |
11% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for ESR1 mutated metastatic breast cancer diagnostics reflected a value of 6.9% during the historical period, 2018 to 2022.
During this period, there were several advancements in the diagnostic tools and treatment options for ESR1 mutated metastatic breast cancer patients. In 2018, the FDA granted accelerated approval for a diagnostic test that can identify patients with ESR1 mutations who may benefit from a specific treatment. In 2019, the American Society of Clinical Oncology published updated guidelines for treating advanced breast cancer, highlighting the importance of genomic testing to identify patients with ESR1 mutations.
In addition, there were several key players in the market that made significant contributions to the development and commercialization of diagnostic tests for ESR1 mutated metastatic breast cancer. These included Myriad Genetics, Foundation Medicine, and Guardant Health.
Overall, the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market showed significant growth potential during the period between 2018 and 2021, with advancements in diagnostic tools and treatment options, but also faced challenges related to pricing and regulatory issues.
Thus, the market for ESR1 mutated metastatic breast cancer diagnostics is expected to register a CAGR of 11% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of ESR1 Mutated Metastatic Breast Cancer Diagnostics Market?
Increasing prevalence of breast cancer favoring growth of market
Breast cancer is one of the most commonly diagnosed cancers among women worldwide, and the incidence of breast cancer is increasing globally. As a result, there is a growing need for personalized treatment options for patients with specific genetic mutations such as ESR1 mutations.
There have been significant advancements in diagnostic technologies, including genetic testing, imaging, and biomarker analysis, which have enabled the identification of ESR1 mutations in breast cancer patients more accurately and quickly. The trend toward personalized medicine is growing, and there is a need for diagnostic tests that can identify specific genetic mutations in cancer patients to provide personalized treatment options that are tailored to each patient's individual needs.
There has been a significant increase in investment in research and development in the field of breast cancer diagnostics, including the development of new technologies and treatments for ESR1 mutated metastatic breast cancer patients. Regulatory approvals for diagnostic tests that can identify ESR1 mutations in breast cancer patients have increased, which has helped to drive the growth of the market.
Availability of diagnostic tools shaping landscape for ESR1 mutated metastatic breast cancer diagnostics market
Genetic testing: Genetic testing can be used to identify mutations in the ESR1 gene in breast cancer patients. These tests can be performed on tumor tissue or blood samples.
Imaging tests: Imaging tests such as computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans can be used to monitor disease progression in breast cancer patients with ESR1 mutations.
Biomarker tests: Biomarker tests such as circulating tumor DNA (ctDNA) analysis can be used to monitor disease progression and response to treatment in breast cancer patients with ESR1 mutations.
Hormone receptor testing: Hormone receptor testing can be used to determine if a breast cancer patient has hormone receptor-positive breast cancer, which is a type of breast cancer that is often treated with hormone therapy.
Pathology testing: Pathology testing can be used to examine the tissue samples from a breast cancer biopsy to determine the type and stage of breast cancer and to identify ESR1 mutations.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Faced by the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market?
Limited access to diagnostic tests along with regulatory challenges hampering market growth
The high cost of diagnostic tests and limited insurance coverage can limit patient access to these tests. Many healthcare providers may not be aware of the importance of genetic testing and other diagnostic tests for identifying ESR1 mutations in breast cancer patients.
There are currently limited targeted therapies available for the treatment of ESR1 mutated metastatic breast cancer, which can limit the impact of diagnostic testing. Regulatory hurdles can slow down the approval and adoption of new diagnostic tests and targeted therapies.
Technical challenges associated with genetic testing, including the complexity of the testing process and the need for specialized expertise and equipment, can limit the widespread adoption of these tests. Genetic testing raises ethical concerns, such as issues related to the privacy of genetic information and the potential for genetic discrimination. Thus, all the aforementioned factors are derailing the growth of ESR1 mutated metastatic breast cancer diagnostics market.
Region-Wise Insights
Robust Regulatory Framework Creating Lucrative Opportunities for North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Market?
Advancements in diagnostic technologies propelling growth of market in North America
Breast cancer is one of the most commonly diagnosed cancers in North America, and the incidence of breast cancer is increasing in the region. There have been significant advancements in diagnostic technologies, including genetic testing, imaging, and biomarker analysis, which have enabled the identification of ESR1 mutations in breast cancer patients more accurately and quickly.
The trend toward personalized medicine is growing in North America, and there is a need for diagnostic tests that can identify specific genetic mutations in cancer patients to provide personalized treatment options that are tailored to each patient's individual needs.
The regulatory framework for diagnostic tests in North America is robust, and there is a high level of scrutiny placed on new diagnostic tests, which helps to ensure their safety and efficacy. North America has one of the highest healthcare spending levels globally, and this has contributed to the growth of the market. Thus, North America is expected to possess 45% market share for ESR1 mutated metastatic breast cancer diagnostics market in 2023.
Increasing Healthcare Spending Favoring ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth in Europe?
Growing emphasis on personalized medicine boosting market growth in Europe
Breast cancer is one of the most common types of cancer in Europe, with an estimated 562,500 new cases diagnosed in 2020 alone. As breast cancer continues to be a major public health concern, the demand for advanced diagnostic tools like ESR1 mutated metastatic breast cancer diagnostics is expected to rise.
As medical research continues to uncover new information about breast cancer mutations, more healthcare providers are becoming aware of the importance of ESR1 testing. This increased awareness has led to greater demand for ESR1 mutated metastatic breast cancer diagnostics, as well as increased funding for research and development in this area.
Precision medicine aims to tailor treatment plans to each individual patient based on their unique genetic makeup. As more medical professionals adopt this approach, the demand for advanced diagnostic tools like ESR1 mutated metastatic breast cancer diagnostics is expected to rise.
Early detection and prevention are critical in the treatment of breast cancer. ESR1 mutated metastatic breast cancer diagnostics can play a key role in identifying mutations at an early stage, allowing for more effective treatment and better patient outcomes.
Thus, Europe is expected to possess 40% market share for ESR1 mutated metastatic breast cancer diagnostics market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Category-Wise Insights
Comprehensive Testing Making Diagnostic Centers go-to Option for ESR1 Mutated Metastatic Breast Cancer Testing?
Assurance of quality in diagnostics centers driving dependency for ESR1 Mutated Metastatic Breast Cancer Testing
Diagnostic centers often have a team of highly skilled and specialized healthcare professionals who have extensive experience in diagnosing and treating cancer, including breast cancer. Diagnostic centers typically have access to the latest imaging and diagnostic equipment, which can help to identify ESR1 mutations in breast cancer patients more accurately and quickly.
Diagnostic centers typically offer a comprehensive range of tests and procedures, including genetic testing, imaging, and biomarker analysis, which can help to identify ESR1 mutations in breast cancer patients and guide personalized treatment options.
Diagnostic centers often work closely with other healthcare providers, including oncologists, surgeons, and radiation therapists, to develop personalized treatment plans for breast cancer patients based on their specific needs.
Diagnostic centers often have strict quality assurance protocols in place to ensure that all tests and procedures are performed accurately and safely. Thus, diagnostic centers are expected to hold 47% market share for ESR1 mutated metastatic breast cancer diagnostics market in 2023.
Market Competition
Key players in the ESR1 mutated metastatic breast cancer diagnostics are Berlin-Chemie, Pfizer, Sanofi, G1 Therapeutics, Inc., Sun Pharma Advanced Research Company, Zenopharm, Arvinas, Sermonix Pharmaceuticals, Roche, AstraZeneca, Novartis, Zentalis Pharmaceuticals, Olema Pharmaceuticals
- Berlin-Chemie has developed a diagnostic test called OnkoSelect ESR1 Mutation Test, which is used to identify ESR1 mutations in breast cancer patients. The OnkoSelect ESR1 Mutation Test is a PCR-based diagnostic test that detects the most common ESR1 mutations in breast cancer patients. The test is designed to be highly sensitive and specific, and it can be used with a range of different tissue samples, including formalin-fixed paraffin-embedded (FFPE) tissue samples.
- Pfizer has developed a targeted therapy called palbociclib (brand name: Ibrance), which is used to treat advanced breast cancer, including ESR1 mutated metastatic breast cancer. Palbociclib is a first-in-class cyclin-dependent kinase 4/6 (CDK4/6) inhibitor that works by blocking the activity of proteins that promote cell division, thereby slowing or stopping the growth of cancer cells. The drug was approved by the US FDA in 2015 for the treatment of advanced breast cancer and has since been approved in several other countries around the world.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 65.15 Million |
|
Market Value in 2033 |
US$ 185 Million |
|
Growth Rate |
CAGR of 11% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in USD Million and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Survey
Hormonal therapy:
- Tamoxifen
- Aromatase inhibitors
- Ovarian suppression
- Fulvestrant
- Elacestrant
Chemotherapy:
- Capecitabine
- Carboplatin
- Cisplatin
- Cyclophosphamide
- Docetaxel
- Others
Targeted therapy:
- Monoclonal antibodies
- Small molecule inhibitors
- Tumor-agnostic treatments
- Immunotherapy
- Pembrolizumab
- Dostarlimab
End User:
- Hospitals
- Clinics
- Research and Academic Institutes
- Diagnostic Centres
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
Frequently Asked Questions
How big is the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market by 2033?
The projected revenue of the market by 2033 is US$ 185 million.
What is the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market CAGR for 2033?
The market CAGR for 2033 is projected to be 11%.
How Big is the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market?
The market is valued at US$ 65.15 million in 2023.
Which region holds a significant share of the ESR1 Mutated Metastatic Breast Cancer Diagnostics market?
North America holds the largest market share.
Why is the North American market growing remarkably fast in the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market?
The North American market is growing remarkably fast in the market due to the increasing incidence of breast cancer.
Table of Content
1. Executive Summary | ESR1 Mutated Metastatic Breast Cancer Diagnostics Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033 5.3.1. Hormonal therapy 5.3.1.1. Tamoxifen 5.3.1.2. Aromatase inhibitors 5.3.1.3. Ovarian suppression 5.3.1.4. Fulvestrant 5.3.1.5. Elacestrant 5.3.2. Chemotherapy 5.3.2.1. Capecitabine 5.3.2.2. Carboplatin 5.3.2.3. Cisplatin 5.3.2.4. Cyclophosphamide 5.3.2.5. Docetaxel 5.3.2.6. Others 5.3.3. Targeted therapy 5.3.3.1. Monoclonal antibodies 5.3.3.2. Small molecule inhibitors 5.3.3.3. Tumor-agnostic treatments 5.3.4. Immunotherapy 5.3.4.1. Pembrolizumab 5.3.4.2. Dostarlimab 5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033 6.3.1. Hospitals 6.3.2. Clinics 6.3.3. Research and Academic Institutes 6.3.4. Diagnostic Centres 6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. South Asia 7.3.5. East Asia 7.3.6. Oceania 7.3.7. MEA 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Treatment 8.2.3. By End User 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Treatment 8.3.3. By End User 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Treatment 9.2.3. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment 9.3.3. By End User 9.4. Key Takeaways 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Treatment 10.2.3. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment 10.3.3. By End User 10.4. Key Takeaways 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. India 11.2.1.2. Malaysia 11.2.1.3. Singapore 11.2.1.4. Thailand 11.2.1.5. Rest of South Asia 11.2.2. By Treatment 11.2.3. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment 11.3.3. By End User 11.4. Key Takeaways 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Treatment 12.2.3. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment 12.3.3. By End User 12.4. Key Takeaways 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Australia 13.2.1.2. New Zealand 13.2.2. By Treatment 13.2.3. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Treatment 13.3.3. By End User 13.4. Key Takeaways 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Treatment 14.2.3. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Treatment 14.3.3. By End User 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Treatment 15.1.2.2. By End User 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Treatment 15.2.2.2. By End User 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Treatment 15.3.2.2. By End User 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Treatment 15.4.2.2. By End User 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Treatment 15.5.2.2. By End User 15.6. United kingdom 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Treatment 15.6.2.2. By End User 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Treatment 15.7.2.2. By End User 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Treatment 15.8.2.2. By End User 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Treatment 15.9.2.2. By End User 15.10. India 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Treatment 15.10.2.2. By End User 15.11. Malaysia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Treatment 15.11.2.2. By End User 15.12. Singapore 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Treatment 15.12.2.2. By End User 15.13. Thailand 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Treatment 15.13.2.2. By End User 15.14. China 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Treatment 15.14.2.2. By End User 15.15. Japan 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Treatment 15.15.2.2. By End User 15.16. South Korea 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Treatment 15.16.2.2. By End User 15.17. Australia 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Treatment 15.17.2.2. By End User 15.18. New Zealand 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Treatment 15.18.2.2. By End User 15.19. GCC Countries 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Treatment 15.19.2.2. By End User 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Treatment 15.20.2.2. By End User 15.21. Israel 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Treatment 15.21.2.2. By End User 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Treatment 16.3.3. By End User 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Berlin-Chemie 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Pfizer 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Sanofi 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. G1 Therapeutics, Inc. 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Sun Pharma Advanced Research Company 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Zenopharm 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Arvinas 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Sermonix Pharmaceuticals 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Roche 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. AstraZeneca 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.11. Novartis 17.1.11.1. Overview 17.1.11.2. Product Portfolio 17.1.11.3. Profitability by Market Segments 17.1.11.4. Sales Footprint 17.1.11.5. Strategy Overview 17.1.11.5.1. Marketing Strategy 17.1.12. Zentalis Pharmaceuticals 17.1.12.1. Overview 17.1.12.2. Product Portfolio 17.1.12.3. Profitability by Market Segments 17.1.12.4. Sales Footprint 17.1.12.5. Strategy Overview 17.1.12.5.1. Marketing Strategy 17.1.13. Olema Pharmaceuticals 17.1.13.1. Overview 17.1.13.2. Product Portfolio 17.1.13.3. Profitability by Market Segments 17.1.13.4. Sales Footprint 17.1.13.5. Strategy Overview 17.1.13.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 8: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 11: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 12: Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 13: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: South Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 15: South Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 17: East Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 18: East Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 19: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 20: Oceania Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 21: Oceania Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 22: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 23: MEA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033 Table 24: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by End User, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 7: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 10: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 11: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 12: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 13: Global Market Attractiveness by Treatment, 2023 to 2033 Figure 14: Global Market Attractiveness by End User, 2023 to 2033 Figure 15: Global Market Attractiveness by Region, 2023 to 2033 Figure 16: North America Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 17: North America Market Value (US$ Million) by End User, 2023 to 2033 Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 22: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 28: North America Market Attractiveness by Treatment, 2023 to 2033 Figure 29: North America Market Attractiveness by End User, 2023 to 2033 Figure 30: North America Market Attractiveness by Country, 2023 to 2033 Figure 31: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 32: Latin America Market Value (US$ Million) by End User, 2023 to 2033 Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 40: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 41: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 43: Latin America Market Attractiveness by Treatment, 2023 to 2033 Figure 44: Latin America Market Attractiveness by End User, 2023 to 2033 Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 46: Europe Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 47: Europe Market Value (US$ Million) by End User, 2023 to 2033 Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 52: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 55: Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 56: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 57: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 58: Europe Market Attractiveness by Treatment, 2023 to 2033 Figure 59: Europe Market Attractiveness by End User, 2023 to 2033 Figure 60: Europe Market Attractiveness by Country, 2023 to 2033 Figure 61: South Asia Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 62: South Asia Market Value (US$ Million) by End User, 2023 to 2033 Figure 63: South Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 64: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 65: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 66: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 67: South Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 68: South Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 69: South Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 70: South Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 71: South Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 72: South Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 73: South Asia Market Attractiveness by Treatment, 2023 to 2033 Figure 74: South Asia Market Attractiveness by End User, 2023 to 2033 Figure 75: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 76: East Asia Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 77: East Asia Market Value (US$ Million) by End User, 2023 to 2033 Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 82: East Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 83: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 85: East Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 86: East Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 87: East Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 88: East Asia Market Attractiveness by Treatment, 2023 to 2033 Figure 89: East Asia Market Attractiveness by End User, 2023 to 2033 Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 91: Oceania Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 92: Oceania Market Value (US$ Million) by End User, 2023 to 2033 Figure 93: Oceania Market Value (US$ Million) by Country, 2023 to 2033 Figure 94: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 95: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 96: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 97: Oceania Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 98: Oceania Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 99: Oceania Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 100: Oceania Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 101: Oceania Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 102: Oceania Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 103: Oceania Market Attractiveness by Treatment, 2023 to 2033 Figure 104: Oceania Market Attractiveness by End User, 2023 to 2033 Figure 105: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 106: MEA Market Value (US$ Million) by Treatment, 2023 to 2033 Figure 107: MEA Market Value (US$ Million) by End User, 2023 to 2033 Figure 108: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 109: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 110: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 111: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 112: MEA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033 Figure 113: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033 Figure 114: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033 Figure 115: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 116: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 117: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 118: MEA Market Attractiveness by Treatment, 2023 to 2033 Figure 119: MEA Market Attractiveness by End User, 2023 to 2033 Figure 120: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports
